Alzheimer's, Weight loss and Lilly

Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...
In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...
The race is on for new drugs that suppress appetite, improve glucose regulation and can replace injections. But do they ...
Eli Lilly expects its experimental weight loss pill, orforglipron, to receive approval as early as next year, CEO David Ricks told Bloomberg Jan. 13, according to a Wall Street Journal report.
Novo Nordisk (NVO) announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a ...
Eli Lilly & Co. ( LLY) thinks its next experimental weight-loss pill could get approved as soon as early 2026.
Interestingly, celebrities like Elon Musk, Oprah Winfrey and Amy Schumer, among others, have also endorsed drugs like Ozempic ...
Eli Lilly expects its experimental weight loss pill, orforglipron, to be approved as soon as early next year, CEO David Ricks told Bloomberg. Eli Lilly and Novo Nordisk, which dominate the ...
In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...